| International Session（Symposium）3(JSGE・JSH・JSGS・JSGCS) |
| Fri. November 1st 9:30 - 11:30 Room 4: Portopia Hotel South Wing Portopia Hall |
Longitudinal outcome of steatotic liver disease and treatment target
|
|||
| Nobuharu Tamaki1, Shun-Ichi Wakabayashi2, Masayuki Kurosaki1 | |||
| 1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 2Division of Gastroenterology, Department of Medicine, Shinshu University School of Medicine | |||
|
|||
|
|||
| Aim: New nomenclature has been proposed for steatotic liver disease and its subgroups of MASLD, MetALD, and ALD. However, the clinical significance of the classification for liver-related events (LRE) and cardiovascular events (CVD) is unknown. In addition, factors associated with a high risk of events and treatment targets are also unknown. Methods: A total of 761400 patients with MASLD, MetALD, and ALD were investigated for LRE and CVD incidence. Results: The 5-year LRE incidence in patients with MASLD, MetALD, and ALD was 0.06%, 0.12% and 0.27%, respectively. In addition, the 5-year CVD incidences were 1.1%, 0.9%, and 0.7%, respectively. In patients with MASLD, LRE incidence increased in a dose-dependent manner with increasing ALT level, whereas CVD incidence was not associated with ALT level. LRE and CVD incidence were significantly higher in patients with HbA1c ≥7% than in those with <7%. Patients with HbA1c ≥7% were stratified by subsequent HbA1c improvement (<7%) or non-improvement (≥7%). Comparing patients with non-improvement, the adjusted hazard ratio (95% confidence interval) for LRE in patients with HbA1c improvement was 0.55 (0.3-1.0). Conclusion: The classification of MASLD, MetALD and ALD is clinically relevant in relation to LRE and CVD risk. In MASLD, ALT and HbA1c can be used as predictive markers of complications, and HbA1c as a therapeutic target. |
|||
|
Index Term 1: MASLD Index Term 2: liver-related event |
|||
| Page Top | |||